C-reactive protein but not atrial dysfunction predicts recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function
暂无分享,去创建一个
[1] H. Neuberger,et al. Discordant Regulation of CRP and NT‐proBNP Plasma Levels After Electrical Cardioversion of Persistent Atrial Fibrillation , 2006, Pacing and clinical electrophysiology : PACE.
[2] E. Varol,et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. , 2006, The American journal of cardiology.
[3] P. Ellinor,et al. C-Reactive protein in lone atrial fibrillation. , 2006, The American journal of cardiology.
[4] E. Watanabe,et al. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. , 2006, International journal of cardiology.
[5] S. Mouly,et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. , 2006, Archives of internal medicine.
[6] D. Katritsis. Is atrial fibrillation an inflammatory disorder? , 2006, European heart journal.
[7] G. Lip,et al. Is atrial fibrillation an inflammatory disorder?: reply , 2006 .
[8] E. Maltezos,et al. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. , 2006, The American journal of cardiology.
[9] G. Lip,et al. Prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. , 2006, Journal of the American College of Cardiology.
[10] J. Zarauza,et al. [Relationship between C-reactive protein level and early recurrence of atrial fibrillation after electrical cardioversion]. , 2006, Revista espanola de cardiologia.
[11] J. Zarauza,et al. Relación entre concentraciones de proteína C reactiva y recurrencia precoz de la fibrilación auricular tras cardioversión eléctrica , 2006 .
[12] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[13] K. Chandrasekaran,et al. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. , 2005, Journal of the American College of Cardiology.
[14] S. Yusuf,et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. , 2005, Journal of the American College of Cardiology.
[15] C. Pandozi,et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. , 2005, Journal of the American College of Cardiology.
[16] M. Chung,et al. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion , 2005, Heart.
[17] D. Kremastinos,et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. , 2005, The American journal of cardiology.
[18] C. Boos. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. , 2004, European heart journal.
[19] R. D. Murray,et al. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. , 2004, The American journal of cardiology.
[20] B. Wożakowska-Kapłon. Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation. , 2004, The American journal of cardiology.
[21] J. Mathew,et al. A multicenter risk index for atrial fibrillation after cardiac surgery. , 2004, JAMA.
[22] D. Mark,et al. B-type natriuretic peptide - a biomarker for all seasons? , 2004, The New England journal of medicine.
[23] Daniel Levy,et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. , 2004, The New England journal of medicine.
[24] M. Drazner,et al. B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.
[25] B. Lévy,et al. Angiotensin II Angiogenic Effect In Vivo Involves Vascular Endothelial Growth Factor- and Inflammation-Related Pathways , 2002, Laboratory Investigation.
[26] E. Picano,et al. Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation. , 2002, Journal of the American College of Cardiology.
[27] Michael R. Rosen,et al. Pathophysiology and Prevention of Atrial Fibrillation , 2001, Circulation.
[28] M. Russo,et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. , 1997, Circulation.
[29] M. Allessie,et al. Electrophysiologic mechanisms of perpetuation of atrial fibrillation. , 1996, The American journal of cardiology.
[30] W. Kannel,et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. , 1982, The New England journal of medicine.
[31] J Haaksma,et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? , 1998, Journal of the American College of Cardiology.
[32] C-reactive protein; , 2022 .